Clinical Trials in San Francisco

Showing 8321-8340 of 12,991 trials

Bococizumab HIV Evaluation (B-HIVE) Study

NCT02524106

B-HIVE is a Phase 3, double blind, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of bococizumab 150 mg subcutaneously every 2 weeks to bococizumab placebo subcutaneously every 2 weeks for LDL-C lowering in HIV-infected subjects.

DyslipidemiaCardiovascular Disease

University of California, San Francisco11 participantsStarted Aug 2016

San Francisco, California, United States • San Francisco, California, United States • San Francisco, California, United States

COMPLETEDPhase 2< 1 mile

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570

The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Participants age 6-11 years will receive oral liquid formulation and participants 12-17 years will receive solid oral capsule or liquid oral solution. Children ages 6-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks. This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of FC.

Functional Constipation in Children Ages 6-17 Years

Forest Laboratories173 participantsStarted Nov 2015

Hot Springs, Arkansas, United States • Little Rock, Arkansas, United States • Anaheim, California, United States +59 more locations

Bococizumab HIV Evaluation (B-HIVE) Study

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Find Trials by Condition in San Francisco

Effectiveness of a Behavioral Treatment Program for Attention Deficit Hyperactivity Disorder, Inattentive Type

Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood

Study of Automated Care Pathway for Patients With Chronic Obstructive Pulmonary Disease (COPD)

Aides in Respiration Health Coaching for COPD

Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry

Intervening to Prevent Youth Access to Marijuana Phase II

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

Medical Abortion Self-Confirmation (MASC)

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2